Noah Graham

Noah Graham

Auto-generated profile, based on publicly available information

Noah Graham

Dana-Farber Cancer Institute 3 Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2024 in European Journal of Cancer
Verified
Journal Article
Closed access
PTPaolo Tarantino
Paolo Tarantino
OAOgheneochuko Ajari
Ogheneochuko Ajari
NGNoah Graham
Noah Graham
JVJulie Vincuilla
Julie Vincuilla
TPTonia Parker
Tonia Parker
STSara M. Tolaney
Sara M. Tolaney

3 December 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
FLFilipa Lynce
Filipa Lynce
NGNoah Graham
Noah Graham
BKBose S. Kochupurakkal
Bose S. Kochupurakkal
HNHuy Nguyen
Huy Nguyen
BBBrittany Bychkovsky
Brittany Bychkovsky
STSara M. Tolaney
Sara M. Tolaney
Purpose: We explored the efficacy of PARP inhibition combined with sapacitabine, an orally bioavailable prodrug of the deoxycytidine analog 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine, in patients with germline BRCA1/2–mutated HER2-negative metastatic breast cancer. Patients and Methods: In this phase Ib investigator-sponsored study of sapacitabine and olaparib, patients who were PARP inhibitor–naïve were enrolled. The primary objective was determination of the recommended phase 2 dose (RP2D) of sapacitabine with olaparib. Archival samples were subjected to IHC for biomarkers of homologous recombination repair (HRR) deficiency and replication stress. Serial blood samples were collected for ctDNA analysis. Results: Ten patients (3 BRCA1 and 7 BRCA2) were enrolled. The RP2D was not determined due to hematologic toxicities. The objective response rate (ORR) was 50% (95% confidence interval, 18.7%–81.3%), with median progression-free survival (mPFS) of 9.7 months (95% confidence interval, 8.02–not estimable). Three patients had clinical benefit greater than 15 months, including two who remained on trial for more than 40 months. Tumors from responding patients demonstrated HRR deficiency and/or replication stress by IHC. At progression, ctDNA from two patients had evidence of BRCA reversion mutations associated with a microhomology-mediated end-joining signature, and three patients had acquired putative nonreversion mechanisms of resistance. Conclusions: Sapacitabine with olaparib produces high rates of hematologic toxicity. However, the ORR of 50%, mPFS of 9.7 months, and durability of response in some patients suggest possible combinatorial benefit. Further exploration of olaparib with different sapacitabine schedules or substitution of a PARP1-selective inhibitor to potentially decrease hematologic toxicity is warranted.

6 November 2026
Verified
Other
Open access
ESElia Seguí
Elia Seguí
JZJorge Gomez Tejeda Zañudo
Jorge Gomez Tejeda Zañudo
NGNoah Graham
Noah Graham
PKPatrick T. Kurnia
Patrick T. Kurnia
APAndrea N. Perry
Andrea N. Perry
JLJosé Pablo Leone
José Pablo Leone
Purpose:Human epidermal growth factor receptor 2 (HER2)–positive breast cancer brain metastases (BCBM) frequently harbor PI3K/AKT/mTOR alterations. Preclinical HER2+ BCBM models demonstrated durable tumor regression with dual PI3K and mTOR inhibition. Our phase II trial evaluated paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor, combined with trastuzumab. Patients and Methods:Eligible patients had active/progressive HER2+ BCBM and could have received prior therapies; leptomeningeal disease was excluded. The trial included a safety run-in to determine the recommended phase II dose (RP2D), followed by expansion cohorts. The primary endpoint was confirmed central nervous system (CNS) objective response rate (ORR) per Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria at the RP2D. Paired plasma and cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) was analyzed using ultralow-pass whole-genome sequencing (ULP-WGS) and whole-exome sequencing (WES). Results:Seventeen patients were treated (median age, 44 years; median 5 prior therapy lines). Paxalisib 30 mg daily plus trastuzumab was established as the RP2D. Among 12 patients treated at the RP2D, no confirmed CNS responses occurred [CNS ORR, 0%; 95% confidence interval (CI), 0%–26.5%], and the study closed for futility. The median overall survival (OS) was 16.5 months. Treatment was feasible, with a safety profile consistent with PI3K/mTOR inhibition. Exploratory ctDNA analyses showed higher tumor fraction (TF) in CSF than plasma, with longitudinal changes in CSF TF paralleling CNS tumor burden. Conclusions:Paxalisib combined with trastuzumab was feasible but did not meet the primary endpoint of CNS ORR in heavily pretreated HER2+ BCBM. Exploratory findings suggest that CSF-derived ctDNA may better capture tumor genomics and treatment response than plasma ctDNA in HER2+ BCBM. Significance:The brain-penetrant dual PI3K/mTOR inhibitor paxalisib plus trastuzumab showed minimal activity in heavily pretreated HER2+ BCBM. Paired liquid biopsy analyses demonstrated that CSF-derived ctDNA may better reflect tumor genomics and treatment response than plasma, supporting CSF for translational studies in this setting. Trial Registration:ClinicalTrials.gov identifier: NCT03765983.

4 February 2026
Verified
Other
Open access
FLFilipa Lynce
Filipa Lynce
NGNoah Graham
Noah Graham
BKBose S. Kochupurakkal
Bose S. Kochupurakkal
HNHuy Nguyen
Huy Nguyen
BBBrittany Bychkovsky
Brittany Bychkovsky
STSara M. Tolaney
Sara M. Tolaney
Supplementary Tables S1-S7 Supplementary Figures S1-S2